During treatment with biologic agents for psoriasis (Pso) in a number of patients a failure may occur and discontinuation with transitioning to another drug or an optimization strategy, consisting in a dose-adjustment or a co-medication with a traditional systemic agent, represent two possible alternatives.
Esposito, M., Prignano, F., Rongioletti, F., Hansel, K., Bianchi, L., Pescitelli, L., et al. (2019). Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 30(5), 441-445 [10.1080/09546634.2018.1529382].
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice
Zangrilli, Arianna;Bianchi, Luca;
2019-01-01
Abstract
During treatment with biologic agents for psoriasis (Pso) in a number of patients a failure may occur and discontinuation with transitioning to another drug or an optimization strategy, consisting in a dose-adjustment or a co-medication with a traditional systemic agent, represent two possible alternatives.| File | Dimensione | Formato | |
|---|---|---|---|
|
Esposito M et al.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
